Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

CALGARY, March 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2007.

"2007 was our most productive year to date, marking a significant expansion of the Company's clinical trial program for REOLYSIN(R) with Phase II studies and combination drug therapy studies being expanded and initiated," said Dr. Brad Thompson, President and CEO of Oncolytics. "This activity was supported by further advances in our preclinical development program, manufacturing, and intellectual property."

Selected Highlights:

Clinical Trial Results Presented

--------------------------------

- Final results from our Phase I U.K. systemic administration trial, and

our U.S. Phase I systemic administration trial at ASCO;

- Positive interim results from our U.K. Phase Ia/Ib combination

REOLYSIN(R) and radiation trial;

Clinical Trial Progress

-----------------------

- Commenced patient enrolment in three combination REOLYSIN(R) and

chemotherapy trials in the U.K.;

- Commenced patient enrolment in a U.S. Phase II trial for patients with

various sarcomas that have metastasized to the lung;

- U.S. National Cancer Institute (NCI) filed a protocol with the U.S.

Food and Drug Administration (FDA) to conduct a Phase II melanoma

trial with REOLYSIN(R);

- Approval to begin a Phase I combination REOLYSIN(R) and

cyclophosphamide trial in the U.K.;

- In January 2008, the NCI filed a protocol with the U.S. FDA to conduct

a Phase I/II ovarian, peritoneal and fallopian tube cancer trial;

- In January 2008, met the criteria to expand to full enrolment of 52

patients in our U.S. Phase II sarcoma trial;

Manufacturing

-------------

- Completed scale up of our manufacturing process to
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – ... Current and Future Opportunities (13-004) , With barriers ... primary cells market continues to increase. In this study, ... often, how satisfied scientists are with commercially available primary ... rate. ,  , Additionally, terminally differentiated cells can ...
(Date:5/16/2013)... 2013 Dr. Stephen Y. Chou, Founder ... “Nanoimprint Lithography and Applications” at IEEE Nano 2013 in ... in 1995 by Chou, is becoming one of the ... combination of sub-10 nm resolution, large area, and low ... both R&D and manufacturing in a broad range of ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... FRANKLIN LAKES, N.J., March 27 BD (Becton,Dickinson ... global medical technology,company, and Direct Relief International, a ... joint volunteer,initiative to strengthen healthcare in Ghana. A ... to Ghana for three weeks and work side-by-side,with ...
... Siemens Will Showcase Its Portfolio of Cardiovascular ... Healthcare, (http://www.usa.siemens.com/healthcare ) will demonstrate how its ... are helping,to "Bring a New Rhythm to ... of the American College of Cardiology (ACC) ...
... Aimed at Developing New Screening Methods and Holds Significant, Potential for Early ... ... Killer, - Biomarker Project holds significant potential for new screening ... the disease before even the ...
Cached Biology Technology:BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 2Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 4Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 5Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3
(Date:5/16/2013)... years old give unprecedented insight into the evolutionary ... most species-rich groups among the modern bony fishes. ... from the Division of Paleontology and Geobiology at ... Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have completed ... assign to the group of bony fishes that ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... in moderating gout risk, new research reveals that vitamin ... acid (urate) levels to a clinically significant degree in ... in combination with allopurinol, appears to have a weak ... according to the results published in the American College ... , Gout is an inflammatory arthritis that causes ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Nov. 1, 2011Researchers at St. Michael,s Hospital have identified ... They also identified two possible treatments to prevent ... the development of new drugs to treat heart attacks ... Ni, found that the same kind of blood-clotting in ...
... people can exchange information instantaneously in the digital age, ... freely and rapidly exchange genetic material related to human ... gene transfer (HGT). In a paper appearing in ... by Eric Alm of MIT,s Department of Civil and ...
... Chinese Academy of Sciences found one new species, Aleurodaphis sinojackiae ... forms leaf galls on Jack trees ( Sinojackia xylocarpa ) and is ... ( Hemiptera , Aphididae , Hormaphidinae ). The ... . Aleurodaphis was established in 1917 by van der ...
Cached Biology News:Researchers pinpoint possible new cause for unexplained miscarriages 2MIT: Bacteria may readily swap beneficial genes 2MIT: Bacteria may readily swap beneficial genes 3